Cardinal Health extends CVS deal through 2032. 16 analysts rate Cardinal Health stock Buy

Published on 10/13/2026 at 11:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fiscal 2027 non-GAAP earnings per share outlook is USD 12.40-12.60. Cardinal Health stock costs EUR 213.55 on October 13, 2026, 0.64 percent above EUR 212.20.

Cardinal Health extended its CVS Health pharmaceutical distribution agreements through June 30, 2032.
Fiscal 2027 non-GAAP earnings per share guidance remains USD 12.40 to USD 12.60.
The stock was EUR 213.55 at Lang & Schwarz on October 13, 2026, 0.64 percent above the October 9 Xetra close.
Sixteen of 19 analysts rate the stock Buy, with a consensus target of USD 266.56.

Schwarzweiß-Reportage an der Verladerampe eines Pharma-Distributionszentrums — Cardinal Health Inc. zeigt eine SW-Reportage der Verladerampe im Pharma-Lager ISIN US14149Y1082, Illustration mit AI erstellt.

Cardinal Health (ISIN US14149Y1082) was trading at EUR 213.55 at Lang & Schwarz on October 13, 2026, 0.64 percent above the Xetra close of October 9, 2026 at EUR 212.20. On October 1, 2026, the company extended its pharmaceutical distribution agreement with CVS Health through June 30, 2032, while 16 of 19 analysts rated Cardinal Health stock Buy.

CVS agreement preserves a major relationship

According to Cardinal Health on October 1, 2026, the binding letter of intent keeps the existing scope of distribution services in place through June 30, 2032. The company did not disclose financial terms, so the visible value of the agreement is its duration and customer continuity rather than a booked contract amount.

The filing also reaffirmed fiscal 2027 non-GAAP earnings per share growth of 13 percent to 15 percent and an outlook of USD 12.40 to USD 12.60 per share. The SEC filing dated October 1, 2026, also records long-term non-GAAP earnings per share growth guidance of 12 percent to 14 percent.

What does the CVS extension change?

The agreement gives Cardinal Health a defined distribution relationship through 2032, but the source provides no contract value or margin commitment. That makes the next earnings update important for testing whether the 13 percent to 15 percent fiscal 2027 earnings growth outlook is translating into reported results.

Analysts keep a positive rating balance

MarketBeat reported on October 11, 2026, that 16 analysts rated Cardinal Health Buy and three rated it Hold, producing a Moderate Buy consensus and an average target of USD 266.56. The same report listed Wells Fargo increasing its target from USD 245.00 to USD 277.00 on August 12, 2026, while Morgan Stanley raised its target from USD 255.00 to USD 265.00 on the same date.

Key dates and market position

MarketBeat lists a quarterly dividend of USD 0.5158 per share payable on October 15, 2026, and Cardinal Health is scheduled to report first-quarter fiscal 2027 results on November 5, 2026. The companys fiscal 2026 revenue was USD 254.2 billion, up from USD 222.6 billion in fiscal 2025, while net income rose to USD 1.7 billion from USD 1.6 billion.

Cardinal Health had a USD 55.8 billion market capitalization as of October 12, 2026. Its 52-week range was USD 151.87 to USD 258.30 on that date, placing the latest U.S. quote below the yearly high while the euro quote remained above the October 9 Xetra close.

Euro quote holds above Xetra close

Cardinal Health was trading at EUR 213.55 at Lang & Schwarz on October 13, 2026 at 10:59 a.m. CEST, up 0.64 percent versus the Xetra close of October 9, 2026 at EUR 212.20. The further course of trading is shown by the continuously updated real-time quote of Cardinal Health stock.